Amphotericin B use in children: conventional and lipid-based formulations

References

• Drew RH. Polyenes for prevention and treatment of invasive fungal infections. In: Antifungal Therapy. Ghannoum MA, Perfect JR (Eds). New York Infarma Healthcare, USA, 163–183 (2010).
   Google Scholar
• Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis.12, 308–329 (1990).
   PubMedGoogle Scholar
• Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis.30, 710–718 (2000).
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis.45, 807–825 (2007).
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin. Infect. Dis.46, 1801–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Bustamante B, Chapman SW et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis.45, 1255–1265 (2007).
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Resistance to antifungal agents: Mechanisms and clinical impact. Clin. Infect. Dis.46, 120–128 (2008).
   PubMed Web of Science ®Google Scholar
• Roilides E, Lyman CA, Filioti J et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother.46, 1974–1976 (2002).
   PubMed Web of Science ®Google Scholar
• Douglas S. Lipid-based amphotericin B for the treatment of fungal ınfections. Pharmacotherapy19, 306–323 (1999).
   PubMedGoogle Scholar
• Abuhammour W, Habte-Gaber E. Newer antifungal agents. Indian J. Pediatr.71, 253–259 (2004).
   PubMedGoogle Scholar
• Lewis RE, Wiederhold NP, Prince RA et al.In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J. Antimicrob. Chemother.57, 288–293 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Wiederhold NP, Klepser ME et al.In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob. Agents Chemother.49, 945–951 (2005).
   PubMed Web of Science ®Google Scholar
• Ernst EJ, Klepser ME, Pfaller MA et al. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother.44, 1108–1111 (2000).
   PubMed Web of Science ®Google Scholar
• Rogers PD, Pearson MM, Cleary JD et al. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother.50, 811–817 (2002).
   PubMed Web of Science ®Google Scholar
• Sau K, Mambula SS, Latz E et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem.278, 37561–37568 (2003).
   PubMed Web of Science ®Google Scholar
• Ben Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: Immunopharmacology of modern antifungals. Clin. Infect. Dis.47, 226–235 (2008).
   PubMedGoogle Scholar
• Gigliotti F, Shenep JL, Lott L et al. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis.156, 784–789 (1987).
   PubMed Web of Science ®Google Scholar
• Andes D, Stamsted T, Conklin R et al. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother.45(3), 922–926 (2001).
   PubMed Web of Science ®Google Scholar
• Vitale RG, Meis JF, Mouton JW et al. Evaluation of the post-antifungal effect [PAFE] of amphotericin B and nystatin against 30 Zygomycetes using two different media. J. Antimicrob. Chemother.52, 65–70 (2003).
   PubMedGoogle Scholar
• Al Dhaheri RS, Douglas LJ. Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob. Agents Chemother.52, 1884–1887 (2008).
   PubMedGoogle Scholar
• Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother.46, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Long L, Kim HG et al. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int. J. Antimicrob. Agents33, 149–153 (2009).
   PubMedGoogle Scholar
• Clancy CJ, Nguyen MH, Clancy CJ et al. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J. Antimicrob. Chemother.41, 127–130 (1998).
   PubMed Web of Science ®Google Scholar
• Smith D, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit.30(2), 167–172 (2008).
   PubMed Web of Science ®Google Scholar
• Klepser ME, Wolfe EJ, Jones RN et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother.41, 1392–1395 (1997).
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Antifungal agents. In: Textbook of Pediatric Infections Diseases (6th Edition). Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds). Saunders Elsevier, PA, USA, 3272–3278, (2009).
   Google Scholar
• Andes D, Safdar N, Marchillo K et al. Pharmacokinetic-pharmacodynamic comparison of amphoterici B [AMB] and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother.50, 674–684 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Liao G, Hou J et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother.51, 1253–1258 (2007).
   PubMed Web of Science ®Google Scholar
• Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B [AmBisome] and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother.46, 828–833 (2002).
   PubMed Web of Science ®Google Scholar
• Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother.50, 1287–1292 (2006).
   PubMed Web of Science ®Google Scholar
• Hong Y, Shaw PJ, Nath CE et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother.50, 935–942 (2006).
   PubMed Web of Science ®Google Scholar
• Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother.33, 1989–1993 (1989).
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis.182, 274–282 (2000).
   PubMed Web of Science ®Google Scholar
• Groll AH, Lyman CA, Petraitis V et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother.50, 3418–3423 (2006).
   PubMed Web of Science ®Google Scholar
• Bellmann R, Egger P, Djanani A et al. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int. J. Antimicrob. Agents23, 80–83 (2004).
   PubMed Web of Science ®Google Scholar
• Nath CE, McLachlan AJ, Shaw PJ et al. Amphotericin B dose optimization in children with malignant diseases. Chemotherapy53, 142–147 (2007).
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Groll AH, Hempel G et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother.49, 5092–5098 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA et al.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother.50, 2009–2015 (2006).
   PubMed Web of Science ®Google Scholar
• Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother.49, 7–10 (2002).
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Mayr A, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother.52, 3637–3641 (2008).
   PubMed Web of Science ®Google Scholar
• Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med. Mycol.46, 541–546 (2008).
   PubMed Web of Science ®Google Scholar
• Kovacicova G, Hanzen J, Pisarcikova M et al. Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors. J. Infect. Chemother.7, 45–48 (2001) .
   PubMedGoogle Scholar
• Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin. Infect. Dis.36, 14–18 (2003).
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI et al.In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother.46, 1581–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Goldman RD, Koren G. Amphotericin B nephrotoxicity in children. J. Pediatr. Hematol. Oncol.26, 421–426 (2004).
   PubMed Web of Science ®Google Scholar
• Lucas da Silva PS, Iglesias SB. Hypokalemic rhabdomyolysis in a child due to amphotericin B therapy. Eur. J. Pediatr.166, 169–171 (2007).
   PubMedGoogle Scholar
• Mohan UR, Bush A. Amphotericin B-induced hepatorenal failure in cystic fibrosis. Pediatr. Pulmonol.33, 497–500 (2002).
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J.27, 820–826 (2008).
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. Severe hypertension associated with the use of amphotericin B: an appraisal on the reported cases. J. Hyperten.24, 1445 (2006).
   PubMedGoogle Scholar
• Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J. Chemother.12, 463–470 (2000).
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch. Intern. Med.148, 2389–2394 (1988).
   PubMed Web of Science ®Google Scholar
• Alexander BD, Wingard JR, Alexander BD et al. Study of renal safety in amphotericin B lipid complex-treated patients. Clin. Infect. Dis.40(Suppl. 6), 414–421 (2005).
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex [ABLC] vs ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymphoma40, 511–520 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med.340, 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Wingard J, White M, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis.31, 1155–1163 (2000).
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis.35, 359–366 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer MA, Winkelmayer WC, Rubin RH et al. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin. Infect. Dis.41, 301–307 (2005).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis.48, 503–535 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol.46, 2620–2629 (2008).
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer115, 4745–4752, (2009).
   PubMed Web of Science ®Google Scholar
• Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr. Infect. Dis. J.28, 1061–1063 (2009).
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med.331, 1325–1330 (1994).
   PubMed Web of Science ®Google Scholar
• Driessen M, Ellis JB, Cooper PA et al. Fluconazole vs amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J.15, 1107–1112 (1996).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347, 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz G et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351, 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics123, 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet369, 1519–1527 (2007).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis.45, 883–893 (2007).
   PubMed Web of Science ®Google Scholar
• Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin. Infect. Dis.40, 384–391 (2005).
   Google Scholar
• Walsh TJ, Seibel NL, Arndt C et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr. Infect. Dis. J.18, 702–708 (1998).
   Google Scholar
• Herbrecht R, Auvrignon A, Andres E et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunocompromised paediatric patients. Eur. J. Clin. Microbiol. Infect. Dis.20, 77– 78 (2001).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ. Antifungal agents in children. Pediatr. Clin. North Am.52, 895– 915 (2005).
   PubMedGoogle Scholar
• Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis.36, 1221–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347, 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121, 1286–1294 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients – recommendations of the Infectious Diseases Working Party [AGIHO] of the German Society of Hematology and Oncology [DGHO]. Ann. Hematol.88, 97–110 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz S, Thiel E. Cerebral aspergillosis: tissue penetration is the key. Med. Mycol.47(Suppl. 1), 387–393 (2009).
   PubMed Web of Science ®Google Scholar
• Kolve H, Ahlke E, Fegeler W, Ritter J, Jürgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J. Antimicrob. Chemother.64, 383–387 (2009).
   PubMed Web of Science ®Google Scholar
• Moen MD, Lyseng-Willisamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs69, 361–392 (2009).
   PubMed Web of Science ®Google Scholar
• Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B ipid complex [ABLC] treatment in allogeneic hematopoietic cell transplant [HCT] recipients with invasive aspergillosis [IA]. Bone Marrow Transplant.36, 873–877 (2005).
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dismukes WE, Duma RJ et al. Comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med.30, 126–131 (1979).
   Google Scholar
• van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med.337, 15–21 (1997).
   PubMed Web of Science ®Google Scholar
• Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis.47, 123–130 (2008).
   PubMed Web of Science ®Google Scholar
• Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B [AmBisome] compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS11, 1463–1471 (1997).
   PubMed Web of Science ®Google Scholar
• Baddour LM, Perfect JR, Ostrosky-Zeichner L et al. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin. Infect. Dis.40(Suppl. 6), 409–413 (2005).
   PubMed Web of Science ®Google Scholar
• Sharkey PK, Graybill JR, Johnson ES et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDSClin. Infect. Dis.22, 315–321 (1996).
   PubMed Web of Science ®Google Scholar
• Singh N, Dromer F, Perfect JR et al. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin. Infect. Dis.47, 1321–1327 (2008).
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Sutton DA, Linden P et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am. J. Transplant.6, 2365–2374 (2006).
   PubMed Web of Science ®Google Scholar
• Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Micro. Infect. Dis.25, 215–229 (2006).
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis.41, 634–653 (2005).
   PubMed Web of Science ®Google Scholar
• Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis.40, 401–408 (2005).
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin. Microbiol. Rev.20, 115–132 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med.137, 105–109 (2002).
   PubMed Web of Science ®Google Scholar
• Jorgensen KJ, Gotzsche PC, Johansen HK et al. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst. Rev. (1), CD004707 (2006).
   Google Scholar
• Johansen HK, Gotzsche PC, Johansen HK et al. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst. Rev. (2), CD000239 (2002).
   Google Scholar
• Malik IA, Moid I, Aziz Z et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am. J. Med.105, 478–483 (1998).
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis.31, 1155–1163 (2000).
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol.98, 711–718 (1997).
   PubMed Web of Science ®Google Scholar